Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Amundi S.A. is a leading French asset management company, recognized as Europe's largest by assets under management, with approximately €2.3 trillion in 2025, placing it among the top 10 global players. Founded in 2010 through the merger of Crédit Agricole Asset Management and Société Générale Asset Management, it has expanded via strategic acquisitions like Pioneer Investments in 2017 and Lyxor Asset Management in 2021, enhancing its active and passive management capabilities. The company offers a comprehensive range of investment solutions, including UCITS funds for equities and bonds, ETFs, real assets such as real estate and private equity, and alternative investments, tailored for over 100 million retail clients, 600 wealth managers, and 1,000 institutional investors worldwide. Present in 35 countries with 5,500 employees, Amundi emphasizes responsible investing, pioneering sustainable solutions and leading in environmental and social shareholder votes among major peers. It also provides innovative technology platforms like ALTO for portfolio management, supporting the entire savings value chain and financing the real economy through quality products aligned with diverse risk profiles and horizons. Amundi S.A. drives growth via its 2025-2028 strategic plan 'Invest for the future,' focusing on diversification, innovation, and efficiency.
19.71% operating margin is respectable but not wide. ROIC at 6.74%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 3.4%, steady but not accelerating.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€6.40B
▲ +3.4% YoY
Net Income (TTM)
€1.59B
▲ +22.0% YoY
Op. Margin
19.71%
▼ -1.7pp YoY
ROIC
6.74%
▼ -0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€1.73B
▲ +13.5% YoY
Op. Cash Flow (TTM)
€2.16B
▲ +9.9% YoY
Net Debt
-€2.12B
Net Cash Position
Cash & Equiv.
€4.14B
3Y CAGR: +2.9%
Continue Research